With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
News|Articles|February 3, 2026
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle
Author(s)CoverMyMeds
This case study leverages IQVIA data and analytics to explore how one pharmaceutical brand navigated mature lifecycle stages in a competitive class, implementing seamless prior auth strategies with CoverMyMeds where a 22 percentage point claim approval rate lift was observed, on average, helping mitigate decreasing access.
Related to this article
As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.
Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.
Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
Trending on Pharmaceutical Commerce
1
How Early Development Decisions Shape Commercial Readiness for Biologics
2
FAQ: What Comes Next for the 340B Rebate Pilot
3
Why Early, Big-Picture Planning Is Key to Execution Across the CGT Lifecycle
4
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
5